Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director

Sep.22
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.

Key Points

  • Eleftheria (Ria) Kioupritzi has joined Philip Morris International as Director Scientific Affairs (Corporate Affairs).
  • She previously served as Roche's Senior Scientific Communications Director, Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy.
  • Earlier roles at Biogen and Roche included competitive intelligence and monitoring of clinical, regulatory and commercial developments, as well as pipeline and launch work.
  • During her period working in Roche's SMA field, Evrysdi received its initial FDA approval in 2020, an expanded indication in 2022 and approval for a tablet formulation in 2025.

2Firsts

September 22, 2026

Eleftheria (Ria) Kioupritzi has joined Philip Morris International (PMI) as Director Scientific Affairs within Corporate Affairs, moving into the tobacco and nicotine sector after more than 15 years in the biopharmaceutical industry.

Kioupritzi announced the appointment on LinkedIn. Before joining PMI, she worked at Roche, where public professional records list her most recent position as Senior Scientific Communications Director, Neuroscience and Rare Diseases.

Career Spanned Pipeline Intelligence, Regulatory Monitoring and Scientific Communications

Kioupritzi's background spans drug-development intelligence, competitive analysis, medical-affairs-related work and scientific communications.

Earlier in her career at Roche, she worked in global competitive intelligence supporting multiple pipeline assets and participated in cross-functional teams covering product lifecycle management, international medical activities and rare-disease launch preparation.

Her work included tracking development programmes and competitive activity and supporting decision-making around early-stage clinical assets.

Kioupritzi later worked at Biogen in EU+ Customer and Market Insights and competitive intelligence. Public career information describes responsibilities that included monitoring competitors across clinical, regulatory and commercial fronts and assessing the implications for Biogen's portfolio and market strategy.

That experience places regulatory intelligence alongside scientific communications in her professional background, rather than positioning her solely as a communications executive.

After returning to Roche, she moved further into neuroscience and rare diseases. Public records list her as Senior Scientific Communications Director, and she spent several years working in the spinal muscular atrophy (SMA) field.

Evrysdi Passed Several FDA Milestones During Her Time in SMA

Kioupritzi's work in Roche's SMA field overlapped with several U.S. regulatory milestones for Evrysdi (risdiplam), the company's SMA medicine.

The U.S. Food and Drug Administration first approved Evrysdi on August 7, 2020, for patients aged two months and older with SMA. The FDA described it as the second drug approved for the disease and the first oral treatment.

The application received Fast Track designation and Priority Review as well as orphan-drug designation and a Rare Pediatric Disease Priority Review Voucher.

In May 2022, the FDA expanded the label to include infants under two months old. FDA records show the approval extended the U.S. indication across pediatric and adult SMA patients.

In February 2025, the FDA approved a New Drug Application for a 5 mg Evrysdi tablet, adding a formulation that can either be swallowed whole or dispersed in water.

FDA labeling records now list both oral-solution and tablet formulations for Evrysdi.

Kioupritzi's scientific-communications work in the SMA field therefore took place around a medicine undergoing repeated FDA review, label expansion and formulation development. Public information reviewed by 2Firsts, however, does not show that she was a member of Evrysdi's regulatory-submission team or personally led formal interactions with the FDA.

Moving From Pharma Scientific Communications to PMI Scientific Affairs

Kioupritzi's new Scientific Affairs position sits within PMI's Corporate Affairs organization.

PMI has not publicly disclosed her detailed responsibilities, reporting line or whether she will cover specific products or markets.

The company's scientific framework for smoke-free products includes product-design controls, toxicological testing, clinical studies, consumer-perception and behavioral research, and post-market assessment.

PMI says its product-development and assessment methods were partly inspired by approaches used in the pharmaceutical industry and aligned with U.S. FDA guidance for Modified Risk Tobacco Product applications as well as Good Laboratory Practice and Good Clinical Practice principles.

PMI products including IQOS and ZYN have gone through U.S. FDA tobacco-product regulatory pathways, including marketing authorization and MRTP review.

That creates professional overlap with Kioupritzi's earlier experience in pharmaceutical pipeline work, regulatory intelligence, medical engagement and scientific communications.

PMI Continues to Build Smoke-Free Scientific Capabilities

PMI has continued to invest in research and scientific assessment around its smoke-free portfolio.

The company says it has invested more than $16 billion since 2008 in the development, research, scientific substantiation and commercialization of smoke-free products and employs more than 1,600 scientists, engineers and technicians in related work.

Its research capabilities span toxicology, clinical science, systems toxicology, consumer-behavior studies, post-market assessment and regulatory science.

PMI also publishes research through peer-reviewed journals, scientific conferences and its PMI Science platform.

Kioupritzi's career before joining PMI covered drug-development pipelines, competitive intelligence, regulatory monitoring, rare-disease medical engagement and scientific communications. Her move from Roche's neuroscience and rare-disease organization into PMI Scientific Affairs adds another pharmaceutical and life-sciences profile to the scientific functions supporting the tobacco industry's expanding smoke-free portfolio.

Follow 2Firsts for timely updates on global tobacco and nicotine industry developments, corporate strategy and market trends.

Cover Image: Eleftheria Kioupritzi / LinkedIn


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24